← All Nevro CORP filings

Nevro CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NVRO
Nevro CORP
8-K: Globus Medical Completes Acquisition of Nevro Corp. for $5.85 Per Share
Nevro Corp. is now a wholly-owned subsidiary of Globus Medical after the completion of a merger on April 3, 2025, with Nevro shareholders receiving $5.85 per share.
NVRO
Nevro CORP
8-K: Nevro Stockholders Approve Merger with Globus Medical
Nevro Corp. stockholders approved the merger agreement with Globus Medical at a special meeting held on April 2, 2025.
NVRO
Nevro CORP
8-K: Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results Amidst Acquisition Agreement with Globus Medical
Nevro Corp. announced its fourth-quarter and full-year 2024 financial results, highlighting a decrease in revenue but exceeding adjusted EBITDA expectations, while also noting the pending acquisition by Globus Medical.
NVRO
Nevro CORP
8-K: Globus Medical to Acquire Nevro Corp. for $5.85 Per Share, Expanding Musculoskeletal Technology Portfolio
Globus Medical will acquire Nevro in an all-cash transaction for $5.85 per share, aiming to expand treatment options for patients and create a combined medical technology leader.
NVRO
Nevro CORP
8-K: Nevro Announces Preliminary Q4 and Full-Year 2024 Revenue: Exceeds Guidance but Shows Year-Over-Year Decline
Nevro Corp. reports preliminary Q4 and full-year 2024 revenue, exceeding prior guidance for the year but showing a year-over-year decrease.
NVRO
Nevro CORP
8-K: Nevro Reports Mixed Q3 Results, Reaffirms Revenue Guidance, and Raises Adjusted EBITDA Outlook
Nevro Corp. reported a decrease in third-quarter revenue but raised its full-year adjusted EBITDA guidance, highlighting the impact of restructuring efforts and new product launches.
NVRO
Nevro CORP
8-K: Nevro Revises 2024 Guidance Amidst Market Softness, Initiates Strategic Review
Nevro Corp. reported a decrease in second-quarter revenue, revised its full-year 2024 revenue and adjusted EBITDA guidance, and announced a strategic review to explore options for accelerating growth and maximizing stockholder value.
NVRO
Nevro CORP
8-K: Nevro Corp. Announces Results of 2024 Annual Stockholders Meeting
Nevro Corp. held its 2024 Annual Meeting of Stockholders on May 23, 2024, where all director nominees were elected, the selection of PricewaterhouseCoopers LLP as the independent auditor was ratified, and executive compensation was approved on an advisory basis.
NVRO
Nevro CORP
8-K: Nevro Corp. Appoints Christofer Christoforou as Chief Operating Officer
Nevro Corp. has appointed Christofer Christoforou as its new Chief Operating Officer, effective May 15, 2024.
NVRO
Nevro CORP
8-K: Nevro Reports Q1 2024 Results, Raises EBITDA Guidance and Appoints New COO
Nevro Corp. announced its first quarter 2024 financial results, raised its full-year adjusted EBITDA guidance, reaffirmed its revenue guidance, and appointed a new Chief Operating Officer.
NVRO
Nevro CORP
8-K: Nevro Corp. Announces Departure of Chief Accounting Officer
Nevro Corp.'s Chief Accounting Officer, Richard B. Carter, has resigned effective May 10, 2024, and his duties will be assumed by CFO Rod MacLeod.
NVRO
Nevro CORP
8-K: Nevro Corp. Reaches Cooperation Agreement with Engaged Capital, Appoints New Director to Board
Nevro Corp. has entered into a cooperation agreement with Engaged Capital, appointing Kirt P. Karros to its Board of Directors and Audit Committee.
NVRO
Nevro CORP
8-K: Nevro Reports Mixed Q4 Results, Provides 2024 Guidance Amid Restructuring
Nevro Corp. announced its fourth-quarter and full-year 2023 financial results, showing revenue growth but also a net loss, while providing 2024 guidance and highlighting strategic changes.